



Published in final edited form as:

Bioorg Med Chem. 2011 July 01; 19(13): 3965–3972. doi:10.1016/j.bmc.2011.05.029.

Design, synthesis and biological assessment of novel *N*-substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines and 3-substituted 2, 6-dioxopiperidines for TNF- α inhibitory activity

Weiming Luo¹, Qian-sheng Yu¹, Isidro Salcedo¹, Harold W. Holloway¹, Debomoy K. Lahiri², Arnold Brossi^{3,#}, David Tweedie^{1,#}, and Nigel H. Greig^{1,#,*}

¹Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA

²Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202

³School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599, USA

Abstract

Eight novel 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 dithiocarbamates **9** and **10**, *N*-substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines **11–14** and 3-substituted 2, 6-dioxopiperidines **16** and **18** were synthesized as tumor necrosis factor- α (TNF- β) synthesis inhibitors. Synthesis involved utilization of a novel condensation approach, a one-pot reaction involving addition, iminium rearrangement and elimination, to generate the phthalimidine ring required for the creation of compounds **9–14**. Agents were, thereafter, quantitatively assessed for their ability to suppress the synthesis on TNF- β in a lipopolysaccharide (LPS)-challenged mouse macrophage-like cellular screen, utilizing cultured RAW 264.7 cells. Whereas compounds **9**, **14** and **16** exhibited potent TNF- α lowering activity, reducing TNF- α by up to 48% at 30 μ M, compounds **12**, **17** and **18** presented moderate TNF- α inhibitory action. The TNF- α lowering properties of these analogues proved more potent than that of revlimid (**3**) and thalidomide (**1**). In particular, *N*-dithiophthalimidomethyl-3-(phthalimidin-2-yl)-2, 6-dioxopiperidine **14** not only possessed the greatest potency of the analogues to reduce TNF- α synthesis, but achieved this with minor cellular toxicity at 30 μ M. The pharmacological focus of the presented compounds is towards the development of well-tolerated agents to ameliorate the neuroinflammation that is commonly associated with neurodegenerative disorders, epitomized by Alzheimer's disease and Parkinson's disease.

Keywords

thalidomide; revlimid; *N*-substituted EM-12; dithiocarbamates; 3-substituted 2; 6-dioxopiperidines; iminium rearrangement; neurodegenerative diseases; TNF- α inhibition

*Corresponding author: Nigel H. Greig <greign@grc.nia.nih.gov>, Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, BRC Room 05C220, 251 Bayview Blvd., Baltimore, MD 21224, USA.

#David Tweedie, Arnold Brossi and Nigel H. Greig contributed equally to this work as senior authors.

1. Introduction

Inflammation of the central nervous system, neuroinflammation, is now recognized as a key feature of all neurodegenerative disorders that, with the progressively aging population, are becoming increasingly prominent.¹ Alzheimer's disease (AD) and Parkinson's disease (PD) are prime examples of debilitating disorders that impact over 5 million and one million Americans, respectively. Neuroinflammation incorporates a wide spectrum of complex cellular responses that often contribute to the pathogenesis and can ultimately drive the progression of a neurological disorder.^{2a-c} The normal adult brain possesses low or undetectable levels of peripheral inflammatory cell subtypes. In the mature brain a primary intrinsic immune-competent cell type is the microglial cell. In the normal, inactivated state microglial cells display a ramified morphology.^{2c} However, during either chronic or acute neuroinflammation, microglia activation rapidly occurs that results in an alteration in morphology and a subsequent release of many inflammatory mediators.^{2a-c} Key amongst these is the pro-inflammatory cytokine, tumor necrosis-alpha (TNF- α), a potent activator of the immune system that can induce immune cell activation leading to the rapid recruitment of neighboring resting microglia or astrocytes within the adjacent brain microenvironment.^{2b,c}

Pharmacological interventions that are able to reset the fine and often lost balance between resting and activated glial cells could be of significant clinical benefit.^{2c} TNF- α protein is a key candidate therapeutic target as - based on data from many clinical, cell biology and animal studies - abnormal regulation of this protein is strongly associated with an unregulated glial cell activity and resulting neuroinflammation.^{2b} The identification of novel agents which can restore the normal function of activated CNS glial cells by means of reducing the pro-inflammatory effects of TNF- α protein within brain represent a viable mechanism of action for the management of clinical disease.^{2c}

Thalidomide (**1**) (Figure 1) is effective in alleviating erythema nodosum leprosum associated with leprosy and aphthous ulcers in AIDS patients.^{3a-d} Although the mechanism via which this drug ameliorates these inflammatory diseases remains to be fully elucidated, thalidomide is known to induce a wide range of immunomodulatory actions. Amongst this diversity of activities is a TNF- α lowering action, mediated by destabilizing TNF- α mRNA levels at the level of its 3'-untranslated region to reduce the rate of synthesis of TNF- α protein.^{4a,b} As the close thalidomide analogue, lenalidomide (revlimid (**3**)) (Figure 1)), likewise possesses TNF- α action,^{3c,d} the backbone holds promise as a multi-template for development of biologically active compounds. In addition, as thalidomide (**1**) displays a moderate degree of lipophilicity (C log D value -0.83)^{6a} that allows it access to the brain, analogues bearing equivalent physicochemical properties may provide promise in the treatment of neurodegenerative diseases exacerbated by neuroinflammation. Additionally, as the TNF- α activity of **1** is not particularly potent, requiring administration of high doses that are often both sedative and associated with adverse effects,⁵ the synthesis of novel and more effective TNF- α lowering agents is a worthy goal. In this regard, several *N*-substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines and 3-substituted 2, 6-dioxopiperidines are described that demonstrate promising anti-TNF- α potency.

2. Results and discussion

2.1. Chemistry

Prior studies have identified a number of thalidomide analogues with improved TNF- α lowering properties in models of cellular and CNS neuroinflammation. In this regard, compounds in Figure 1 have demonstrated encouraging results regarding anti-TNF- α potency associated with tolerable cellular toxicity.^{6a-d}

N-substituted thalidomide derivatives have been reported with potent antitumor activities.⁷ Indeed, several *N*-alkylated thalidomide analogues have been screened in cell culture and then further evaluated in animals, in which a higher antitumor activity than that of thalidomide was observed.^{8a-f} In general, when a sulfur atom was introduced into the thalidomide pharmacophore, a more potent antitumor activity was detected.⁹ Up to now the biological properties of *N*-dithiocarbamate substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines have not been reported. Based on our unpublished observations and a structural analysis of specific known compounds possessing TNF- α inhibitory activity, we generated two novel *N*-dithiocarbamate substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines, **9** and **10**, as likely TNF- α inhibitors (Scheme 1).

Compounds **11–14** were synthesized as shown in Scheme 1. The rationale underpinning the conception of these agents is based on green chemistry,¹⁰ whereby two potentially active agents may, under appropriate conditions, derive from a single compound; thereby providing a form of ‘medicinal economy’. Specifically, under physiological conditions, the use of a methylene linkage to connect two nitrogen atoms, as in **11–14**, may permit the occurrence of simple metabolism to allow generation of the corresponding 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 (**2**) (Figure 1), glutarimide, dithioglutarimide, phthalimide or dithiophthalimide. Importantly, these latter agents all possess a degree of TNF- α lowering potency.^{6a} Previously, we and others have demonstrated that 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 (**2**) generates TNF- α inhibitory activity with a low cellular toxicity^{6c,e} and that dithiophthalimide is likewise active and well tolerated.^{6a} As illustrated in Table 1, compound **14**, containing such a methylene linkage that simultaneously connects the 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 and dithiophthalimide moieties, proved to be the most potent TNF- α lowering candidate amongst the eleven analyzed compounds.

For the syntheses of compounds **9–14**, we adopted our own novel condensation approach to allow formation of the phthalimidine ring. This one-pot reaction involved addition, rearrangement and elimination. A potential mechanism underpinning this is shown in Figure 2. The process proved to be simple and the product yield was good (ranging from 52% to 89%), thereby providing a shortcut for synthesis of 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 analogues. In chemistry more generally, such dehydration spanning a nitrogen atom to form a lactam is, likewise, interesting and has not previously been reported. By contrast, previously published synthetic routes to yield EM-12 are greater than a single step, as is evident from the work of Luzzio and colleagues^{6f} where synthesis was achieved in 6 steps in a yield of 25%. Other reports describe the use of a radical inducing reagent or UV light. In our one pot reaction, however, synthesis is undertaken at room

temperature and a yield up to 80% is achievable, even if undertaken in neutral or weakly basic reaction mediums.

Consequent to the introduction of hetero-atoms, such as sulfur and nitrogen, into thalidomide that provided significant TNF- α inhibitory activity, we designed compound **16**, in which the 1, 3-carbonyl groups of thalidomide are replaced by sulfonyl groups, and compounds **17a** and **18**, in which the 1, 3-dioxo and 1-oxo of thalidomide were substituted by imino groups, respectively (Scheme 2, Figure 3).

For the synthesis of **17a**, as illustrated in Figure 3, the principal product is **17**.^{6c} This can be attributed to the presence of a 1, 3-H transfer, as depicted in Figure 3, under the reaction conditions indicated. Two primary amino groups may prove more advantageous to support the intramolecular elimination of ammonia. The condensation of reactants 3-iminoisindolinone and **15** normally afforded product **18**, which has been confirmed by two correlative peaks of 3'-H/1-C and 3;-H/3-C in the (¹H-detected) heteronuclear multiple-bond correlation (HMBC) spectrum. Syntheses of compounds **19** and **20** proved straightforward using the methods defined in Scheme 2, and the yield of **20** proved to be high (93%).

2.2. TNF- α inhibitory activity

Inhibition of LPS-induced TNF- α production in RAW 264.7 cells, cell viability and computed lipophilicity (C log *D* value) of assessed compounds **9–14**, **16–20** are shown in Table 1. The biological activities of the above analogues were compared to those of revlimid (**3**). In addition to thalidomide (**1**), **3** is a credible TNF- α inhibitor,^{11a,b} and is both approved for and effective in the for treatment of multiple myeloma and specific myelodysplastic syndromes.^{12a–f} Herein, compounds **9**, **12**, **14** and **16–18** possessed more potent TNF- α inhibitory activity than that of revlimid (**3**) as well as thalidomide (**1**) in our assay model, which has now been extensively characterized.^{6c} Indeed, compounds **9**, **14** and **16** not only showed the most potency as TNF- α inhibitors amongst all eleven assayed compounds (contrasting markedly with revlimid (**3**)) but appeared well tolerated, albeit **14** was associated with a mild decline in cell viability at 30 μ M. Parenthetically, the TNF- α activity of compound **17**, whose chemistry is reported for the first time herein, compares favorably to that reported by Tweedie et al.,^{6c} (agent A10), demonstrating the consistency of the assay across time.

The C log *D* values of our analogues, interestingly, ranged from lipophilic (**9**: +1.39) to water-soluble (**16**: -1.75) (Table 1), suggesting that their potency as TNF- α inhibitors related more to their structural configuration rather than to a physicochemical characteristic, such as lipophilicity, that would be predicted to augment cellular uptake. Clearly, structural configuration together with physicochemical properties impact the ability of a compound to suitably orientate, dock and then appropriately interact with a required target, such as one regulating TNF- α protein synthesis, and are thereby fundamental to its TNF- α lowering effects. However, regulation of TNF- α synthesis by thalidomide (**1**) and analogues is not mediated via a classical receptor or enzyme-based interaction for which structure-activity

relations are generally available but, instead, appears to involve complex post-transcriptional regulatory actions mediated at the level of the 3'-UTR of TNF- α mRNA.^{4a,b}

In general, mRNAs are amenable to several forms of post-transcriptional regulation, which include pre-mRNA splicing and maturation (3' polyadenylation and 5' capping), mRNA nuclear export to the cytoplasm, appropriate sub-cytoplasmic localization, stabilization and translation.^{13a-c} Two major kinds of *trans* acting factors that recognize specific *cis* elements (RNA sequences) within the target mRNA are involved in the regulation of these steps, RNA-binding proteins (RBPs) and microRNAs. For TNF- α gene expression, the role of RBPs has been widely explored, whereas the part of microRNAs remains to be more fully characterized.^{13c,d} For inflammatory cytokines like TNF- α , in particular, but also for IL-2, IL-6 and interferon- γ , synthesis is tightly regulated at the level of mRNA stability, thereby permitting rapid responses to external stimuli, as occurs for LPS. The presence of adenylate-uridylate-rich elements (AREs) within the 3'-UTR of TNF- α mRNA plays a primary role in post-transcriptional repression, targeting it for rapid degradation or inhibition of translation.^{13a,b} p38 MAPK has been implicated as a major signaling cascade facilitating the stability of TNF- α via its 3'-UTR ARE *cis* elements, which have been shown to be mediated through interactions with RBPs.^{13a-d} In particular, proteins such as HuR, whose translocation to the cytoplasm is potentially induced by oxidative stress and other aberrant stimuli,^{13c} have been associated with promoting transcript stabilization. Upon export to the cytoplasm, HuR binds and stabilizes ARE-containing transcripts and conveys them to translational machinery. Conversely, RNA-binding proteins such as tristetraprolin (TTP) and related proteins (e.g., butyrate response factor 1 and 2) have a major regulatory role in accelerating the degradation of bound mRNAs, albeit the precise mechanisms accounting for this degradation are incompletely understood but they include the action of several cellular structures known to breakdown labile mRNAs, the proteasome, exosome and RNA processing-body.^{13a-c}

It is widely accepted that LPS challenge of RAW 264.7 cells extends the half-life of TNF- α mRNA, allowing release of its translational repression. By contrast, administration of thalidomide (**1**) induces an increase in translational blockade and a shortening of the TNF- α mRNA half-life from 30 min to 17 min.^{4a,14a,b} Although yet to be elucidated, interactions between thalidomide analogs and the binding of HUR as well as TTP related RBPs with 3'-UTR *cis* elements likely underpins alterations in the rate of TNF- α synthesis. In this regard, small chemical inhibitors that disrupt HuR:ARE binding have been described.^{14c,d} As yet, insufficient compounds have been assessed to provide structure-activity relations, but such a target, or a strengthening of TTP:ARE binding, represents a potential means via which thalidomide analogs may effectively regulate TNF- α protein levels.

These same properties of thalidomide analogues may or may not be vital for pharmacological interactions with other targets, such as nitric oxide,^{15a,b} known to be regulated by thalidomide (**1**) and are a focus of current studies. In the event that the inhibitory activity of designed compounds proves ideal, in part or in whole, it not only provides a basis to manipulate TNF- α levels to define its pharmacological role in health and disease, but also affords structural information to allow investigation of the target and its regulatory elements.

In this regard, these TNF- α lowering data are sufficiently promising to indicate that further study of the pharmacology and biology of these agents is warranted in models of neurodegenerative diseases where a component of the disease pathology is associated with neuroinflammation.

3. Conclusion

Novel 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 dithiocarbamates **9** and **10**, *N*-substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines **11–14** and 3-substituted 2, 6-dioxopiperidines **16** and **18** were designed, prepared and assessed for TNF- α lowering activity. Synthesis involved a novel condensation approach for the generation of analogues of 2-(2, 6-dioxopiperidin-3-yl)phthalimidine EM-12 (**2**). In addition to *N*-substituted 3-(phthalimidin-2-yl)-2, 6-dioxopiperidines **14** and **9**, 3-(*o*-benzenedisulfonimid-2-yl)-2, 6-dioxopiperidine **16** proved to be a potent anti-TNF- α candidate agent. These novel compounds thereby provide potential promise as immunomodulatory drugs candidates whose biological and pharmacological actions warrant further assessment in animal models of inflammatory disorders. Particularly relevant would be a neuroinflammatory focus, as invariably occurs in neurodegenerative conditions, exemplified by Alzheimer's disease and Parkinson's disease.

4. Experimentals

4.1. Chemistry

Melting points (uncorrected) were measured with a Fisher-Johns apparatus. ^1H NMR, and ^{13}C NMR were recorded on a Bruker (Belleveca, MA) AC-300 spectrometer. MS (*m/z*) data were measured on an Agilent 5973 GC-MS (CI). Elemental analyses were performed by Atlantic Microlab, Inc. (Norcross, GA). All reactions involving non-aqueous solutions were performed under an inert atmosphere.

4.1.1. 1-Hydroxymethyl-3-(*tert*-butoxycarbonylamino)-2, 6-dioxopiperidine (**5**)

—A mixture of 3-(*tert*-butoxycarbonylamino)-2, 6-dioxopiperidine **4** (7.10 g, 31.1 mmol) and formaldehyde (37% solution in water, 37.2 ml) was refluxed under an atmosphere of nitrogen for 0.5 h. After cooling, isolated precipitate was recrystallized with acetone to afford product **5** (5.85 g, 72.9 %) as white crystals: mp 216.5–217.5 °C; ^1H NMR (DMSO- d_6) δ 7.20 (d, J = 6.0 Hz, 1H, NH), 6.04 (t, J = 10.5 Hz, 1H, OH), 5.05–4.92 (m, 2H, CH₂OH), 4.38–4.22 (m, 1H, C3-H), 2.89–2.59 (m, 2H), 1.99–1.83 (m, 2H) and 1.41 (s, 9H, CH₃) ppm; ^{13}C NMR (DMSO- d_6) δ 172.1, 171.9, 155.8, 78.5, 62.7, 51.3, 31.6, 28.5 and 23.6 ppm; MS (CI/CH₄), *m/z* 257 (M-1).

4.1.2. 1-Chloromethyl-3-(*tert*-butoxycarbonylamino)-2, 6-dioxopiperidine (**6**)—

Thionyl chloride (7.35 g, 61.8 mmole) was dropwise added to a solution of compound **5** (5.83 g, 22.6 mmole) in DMF (17 mL) at 0 °C. The mixture was reacted for 1 h maintained at the same temperature. Thereafter, it was poured onto ice (60 g). Precipitate was isolated and was washed with ice water to pH 7 *ca*. The crude product was recrystallized with acetone to afford **6** (5.7 g, 90.5 %) as a white solid: mp 134.0–135.0 °C; ^1H NMR (DMSO- d_6) δ 7.31 (d, J = 6.1 Hz, 1H, NH), 5.49 (s, 2H, CH₂Cl), 4.58–4.30 (m, 1H, C3-H), 3.08–

2.67 (m, 2H), 2.10–1.87 (m, 2H) and 1.48 (s, 9H, CH₃) ppm; ¹³C NMR (DMSO-*d*₆) δ 171.5, 171.1, 155.8, 78.7, 51.3, 48.5, 31.4, 28.5 and 23.3 ppm; MS (CI/CH₄), *m/z* 276 (M⁺).

4.1.3. 3-Amino-1-chloromethyl-2, 6-dioxopiperidine trifluoroacetate (7)—

Trifluoroacetic acid (28.4 mL) was dropwise added into a solution of compound **6** (4.0 g, 14.5 mmol) in dichloromethane (274 mL) at room temperature. The mixture was reacted for 22.5 h under an atmosphere of nitrogen at the same temperature. Thereafter, it was concentrated and precipitated with ether. Isolated solid was dried overnight to afford product **7** (4.05 g, 96.2 %) as a purplish salt; ¹H NMR (DMSO-*d*₆) δ 8.80 (s, 3H, NH₃⁺), 5.56 and 5.50 (AB system, *J* = 9.2 Hz, 2H, CH₂Cl), 4.51–4.28 (m, 1H, C3-H), 3.01–2.71 (m, 2H) and 2.31–1.90 (m, 2H) ppm; ¹³C NMR (DMSO-*d*₆) δ 170.2, 169.2, 159.0, 158.5, 49.9, 48.1, 30.6 and 21.3 ppm; MS (CI/CH₄), *m/z* 288 (M-2).

4.1.4. 2-(1-Chloromethyl-2, 6-dioxopiperidin-3-yl)phthalimidine (8)—

A mixture of phthalaldialdehyde (2.74 g, 20.4 mmol) and compound **7** (5.94 g, 20.4 mmol) in THF (1.7 L) was stirred under an atmosphere of nitrogen at room temperature for 71 h. Thereafter, solvent was removed, and the crude product was purified with chromatography on silica gel (CH₃CN/CH₂Cl₂ = 1/4) to afford product **8** (3.1 g, 51.7 %) as a white solid: mp 180.5–181.0 °C; ¹H NMR (CDCl₃) δ 7.94–7.43 (m, 4H, Ar-H), 5.59 and 5.51 (AB system, *J* = 8.1 Hz, 2H, CH₂Cl), 5.30–5.19 (m, 1H, C3'-H), 4.50 and 4.36 (AB system, *J* = 16.5 Hz, 2H, C3-H), 3.15–2.85 (m, 2H) and 2.46–2.13 (m, 2H) ppm; ¹³C NMR (CDCl₃) δ 169.4, 169.3, 168.6, 141.4, 132.1, 131.3, 128.3, 124.2, 122.9, 52.5, 47.2, 47.1, 31.9 and 22.3 ppm; MS (CI/CH₄), *m/z* 294 (M+2). Anal. Calcd for C₁₄H₁₃ClN₂O₃: C, 57.44; H, 4.48; N, 9.57. Found: C, 57.37; H, 4.46; N, 9.17.

4.1.5. [3-(1-Oxo-1, 3-dihydro-1*H*-isoindol-2-yl)-2, 6-dioxopiperidin-1-yl]methyl cyclohexyldithiocarbamate (9)—

A mixture of compound **8** (37.0 mg, 0.126 mmol), carbon disulfide (19.2 mg, 0.252 mmol) and cyclohexylamine (25.1 mg, 0.253 mmol) in acetonitrile (7 mL) was reacted for 42.5 h under an atmosphere of nitrogen at room temperature. After removing solvent, the residues were separated with chromatography on silica gel (MeOH/CH₂Cl₂ = 1/20) to afford product **9** (36.0 mg, 66.7%) as a yellow crystals: mp 128.0–129.0 °C; ¹H NMR (CDCl₃) δ 8.75 (s, 1H, NH), 7.95–7.38 (m, 4H, Ar-H), 5.31–5.01 (m, 3H, C3'-H and CH₂S), 4.49–4.25 (m, 2H, C3-H) and 3.14–1.05 (m, 15H, C5,4-H and cyclohex-H) ppm; ¹³C NMR (CDCl₃) δ 191.2, 171.3, 170.2, 169.3, 141.3, 132.1, 131.3, 128.3, 124.2, 122.9, 55.8, 52.6, 47.4, 43.3, 31.8, 31.4, 25.3, 24.7 and 22.3 ppm; MS (CI/CH₄), *m/z* 432 (MH⁺). Anal. Calcd for C₂₁H₂₅N₃O₃S₂: C, 58.44; H, 5.84; N, 9.74. Found: C, 58.05; H, 5.88; N, 9.47.

4.1.6. [3-(1-Oxo-1, 3-dihydro-1*H*-isoindol-2-yl)-2, 6-dioxopiperidin-1-yl]methyl piperidin-1-carbodithioate (10)—

A mixture of compound **8** (33.0 mg, 0.113 mmol), carbon disulfide (17.2 mg, 0.226 mmol) and piperidine (19.2 mg, 0.225 mmol) in acetonitrile (6 mL) was reacted for 46.0 h under an atmosphere of nitrogen at room temperature. After removing solvent, the residues were separated with chromatography on silica gel (MeOH/CH₂Cl₂ = 1/15) to afford product **10** (33.5 mg, 71.0 %) as a white powder: mp 180.0–181.5 °C; ¹H NMR (CDCl₃) δ 7.90–7.41 (m, 4H, Ar-H), 5.79 and 5.68 (AB

system, $J = 14.5$ Hz, 2H, CH₂S), 5.29–5.18 (m, 1H, C3'-H), 4.49 and 4.30 (AB system, $J = 16.5$ Hz, 2H, C3-H), 4.24 (s, br, 2H, pip-C2,6-H), 3.81 (s, br, 2H, pip-C2,6-H), 3.09–2.81 (m, 2H), 2.41–2.11 (m, 2H) and 1.79–1.54 (m, 6H, pip-C3,4,5-H) ppm; ¹³C NMR (CDCl₃) δ 192.7, 170.3, 169.2, 141.4, 131.9, 131.4, 128.1, 124.0, 122.8, 52.4, 51.6, 47.1, 46.4, 32.0, 25.8, 24.1 and 22.5 ppm; MS (CI/CH₄), m/z 258 (M-159). Anal. Calcd for C₂₀H₂₃N₃O₃S₂: C, 57.53; H, 5.55; N, 10.06. Found: C, 57.80; H, 5.38; N, 9.95.

4.1.7. *N*-(1, 3-dioxopiperidin-2-yl)methyl-3-(1-oxo-1, 3-dihydro-1*H*-isoindol-2-yl)-2, 6-dioxopiperidine (11)—A mixture of glutarimide (36.0 mg, 0.318 mmol) and potassium hydroxide (42 mg, 0.750 mmol) in acetonitrile (42 mL) was stirred for an hour at room temperature. Thereafter, compound **8** (93.0 mg, 0.318 mmol) was added to the reaction system and stirred for a further 17 h under an atmosphere of nitrogen at the same temperature. After removing solvent, the residues were separated with chromatography on silica gel (CH₃CN/CH₂Cl₂ = 1/3) to afford product **11** (68.0 mg, 57.9 %) as a white solid: mp 216.5–217.0 °C; ¹H NMR (CDCl₃) δ 7.88 (d, $J = 9.0$ Hz, 1H, C7-H), 7.57 (d, $J = 8.5$ Hz, 1H, C4-H), 7.46 (t, $J = 9.0$ Hz, 2H, C5,6-H), 5.85 (s, 2H, CH₂N₂), 5.19–5.10 (m, 1H, C3'-H), 4.52 and 4.35 (AB system, $J = 16.5$ Hz, 2H, C3-H), 3.08–1.81 (m, 10H, C5',4'-H and glu-H) ppm; ¹³C NMR (CDCl₃) δ 171.9, 170.3, 169.4, 169.3, 141.6, 132.0, 131.7, 128.2, 124.1, 123.0, 52.8, 47.4, 45.0, 32.9, 32.2, 22.8 and 17.0 ppm; MS (CI/CH₄), m/z 300 (M-69). Anal. Calcd for C₁₉H₁₉N₃O₅H₂O: C, 58.91; H, 5.46; N, 10.85. Found: C, 59.17; H, 5.38; N, 10.61.

4.1.8. *N*-(1, 3-dithioxopiperidin-2-yl)methyl-3-(1-oxo-1, 3-dihydro-1*H*-isoindol-2-yl)-2, 6-dioxopiperidine (12)—A mixture of dithioglutarimide (46.2 mg, 0.318 mmol), potassium hydroxide (42 mg, 0.750 mmol) and compound **8** (93.0 mg, 0.318 mmol) in acetonitrile (42 mL) was stirred for 16 h under an atmosphere of nitrogen at room temperature. After removing solvent, the residues were separated with chromatography on silica gel (CH₃CN/CH₂Cl₂ = 1/3) to afford product **12** (33.0 mg, 25.8 %) as a yellow solid: mp 218.0–220.0 °C; ¹H NMR (CDCl₃) δ 7.91–7.43 (m, 4H, Ar-H), 5.22–5.12 (m, 1H, C3'-H), 5.07 and 4.94 (AB system, $J = 10.1$ Hz, 2H, CH₂N₂), 4.50 and 4.39 (AB system, $J = 16.5$ Hz, 2H, C3-H), 3.09–1.89 (m, 10H, C5',4'-H and thioglu-H) ppm; ¹³C NMR (CDCl₃) δ 201.7, 170.9, 169.8, 169.5, 141.6, 132.2, 131.6, 128.4, 124.4, 123.1, 53.1, 48.1, 43.6, 37.6, 32.0, 22.6 and 21.2 ppm; MS (CI/CH₄), m/z 404 (M+3). Anal. Calcd for C₁₉H₁₉N₃O₃S₂H₂O: C, 54.40; H, 5.04; N, 10.01. Found: 54.08; H, 4.42; N, 9.48.

4.1.9. *N*-Phthalimidomethyl-3-(1-oxo-1, 3-dihydro-1*H*-isoindol-2-yl)-2, 6-dioxopiperidine (13)—A mixture of phthalimide (46.8 mg, 0.318 mmol) and potassium hydroxide (42 mg, 0.750 mmol) in acetonitrile (42 mL) was stirred for an hour at room temperature. Thereafter, compound **8** (93.0 mg, 0.318 mmol) was added to the reaction system and stirred for another 17 h under an atmosphere of nitrogen at the same temperature. After removing solvent, the residues were separated with chromatography on silica gel (CH₃CN/CH₂Cl₂ = 1/3) to afford product **13** (67.0 mg, 52.2 %) as a white solid: mp 209.5–210.5 °C; ¹H NMR (CDCl₃) δ 7.95–7.40 (m, 8H, Ar-H), 5.83 and 5.72 (AB system, $J = 13.5$ Hz, 2H, CH₂N₂), 5.39–5.23 (m, 1H, C3'-H), 4.54 and 4.34 (AB system, $J = 16.6$ Hz, 2H, C3-H), 3.10–2.82 (m, 2H) and 2.46–2.11 (m, 2H) ppm; ¹³C NMR (CDCl₃) δ

170.3, 169.6, 169.3, 167.0, 141.7, 134.3, 132.0, 131.7, 131.6, 128.2, 124.2, 123.6, 123.0, 52.5, 47.1, 43.6, 32.1 and 22.7 ppm; MS (CI/CH₄), m/z 390 (M-13). Anal. Calcd for C₂₂H₁₇N₃O₅: C, 65.50; H, 4.25; N, 10.42. Found: C, 65.32; H, 4.12; N, 10.21.

4.1.10. N-Dithiophthalimidomethyl-3-(1-oxo-1, 3-dihydro-1*H*-isoindol-2-yl)-2, 6-dioxopiperidine (14)—A mixture of dithiophthalimide (57.0 mg, 0.318 mmol) and potassium hydroxide (42 mg, 0.750 mmol) in acetonitrile (42 mL) was stirred for an hour at room temperature. Thereafter, compound **8** (93.0 mg, 0.318 mmol) was added to the reaction system and stirred for another 17 h under an atmosphere of nitrogen at the same temperature. After removing solvent, the residues were separated with chromatography on silica gel (CH₃CN/CH₂Cl₂ = 1/3) to afford product **14** (17.0 mg, 12.3 %) as a yellow gum. ¹H NMR (CDCl₃) δ 7.98–7.39 (m, 8H, Ar-H), 6.47 (s, 2H, CH₂N₂), 5.31–5.19 (m, 1H, C3'-H), 4.49 and 4.32 (AB system, *J* = 16.3 Hz, 2H, C3-H), 3.09–2.79 (m, 2H) and 2.49–2.07 (m, 2H) ppm; ¹³C NMR (CDCl₃) δ 197.0, 170.4, 169.3, 169.1, 141.5, 134.8, 133.5, 132.0, 131.6, 128.2, 124.2, 123.6, 123.0, 52.5, 49.1, 47.1, 32.2 and 22.7 ppm; MS (CI/CH₄), m/z 383 (M-52). Anal. Calcd for C₂₂H₁₇N₃O₃S₂·1/3 H₂O: C, 59.87; H, 4.03; N, 9.52. Found: C, 59.91; H, 3.71; N, 9.17.

4.1.11. 3-(*o*-Benzenedisulfonimid-2-yl)-2, 6-dioxopiperidine (16)—A mixture of 1, 2-benzenedisulfonyl dichloride (1.00 g, 3.63 mmol), 3-amino-2, 6-dioxopiperidine trifluoroacetate **15** (0.88 g, 3.63 mmol) and triethylamine (1.10 g, 10.87 mmol) in anhydrous THF (100 mL) was first reacted for 1.5 h at room temperature under an atmosphere of nitrogen, and, thereafter, it was refluxed for 24 h under an atmosphere of nitrogen. Following cooling, a grey crude product was filtered. This was recrystallized from hot acetone to provide product **16** (0.77 g, 64.2 %) as a purplish powder: mp 253 °C (dec.); ¹H NMR (DMSO-*d*₆) δ 11.08 (s, 1H, NH), 8.40–8.01 (m, 4H, Ar-H), 5.51–5.40 (m, 1H, C3'-H), 2.96–2.51 (m, 2H) and 2.50–2.30 (m, 2H) ppm; ¹³C NMR (DMSO-*d*₆) δ 172.5, 169.1, 137.4, 135.8, 122.3, 59.0, 31.5 and 24.7 ppm; MS (CI/CH₄), m/z 331 (MH⁺). Anal. Calcd for C₁₁H₁₀N₂O₆S₂: C, 39.99; H, 3.05; N, 8.48. Found: C, 40.57; H, 3.22; N, 8.21.

4.1.12. 3-(1, 3-Diimino-1, 3-dihydro-2*H*-isoindol-¹N-yl)-2, 6-dioxopiperidine (17)—A mixture of 1, 3-diiminoisoindoline (0.50 g, 3.44 mmol), 3-amino-2, 6-dioxopiperidine trifluoroacetate **15** (0.83 g, 3.43 mmol) and triethylamine (0.95 g, 9.39 mmol) in THF (200 mL) was refluxed for 98 h under an atmosphere of nitrogen. After cooling, a grey crude product was filtered. This was recrystallized from hot acetone to afford product **17** (0.67 g, 76.1 %) as a gray powder: mp 246 °C (dec.); ¹H NMR (DMSO-*d*₆) δ 10.72 (s, 1H, CONH), 8.51 and 8.39 (sh, 2H, CCNH and C=NH), 7.90–7.50 (m, 4H, Ar-H), 5.01 (t, *J* = 5.5 Hz, 1H, C3'-H), 2.61 (m, 2-H) and 2.04 (m, 2-H) ppm; ¹³C NMR (DMSO-*d*₆) δ 173.8, 173.5, 170.6, 168.5, 139.8, 136.1, 131.1, 130.3, 121.5, 121.0, 59.2, 30.3 and 26.3 ppm; MS (CI/CH₄), m/z 257 (MH⁺). Anal. Calcd for C₁₃H₁₂N₄O₂: C, 60.93; H, 4.72; N, 21.86. Found: C, 60.89; H, 4.82; N, 21.58.

4.1.13. 3-(1-Oxo-3-imino-1, 3-dihydro-2*H*-isoindol-2-yl)-2, 6-dioxopiperidine (18)—A mixture of 3-iminoisoindolinone (0.50 g, 3.42 mmol), 3-amino-2, 6-dioxopiperidine trifluoroacetate **15** (0.83 g, 3.43 mmol) and triethylamine (0.94 g, 9.29

mmol) in THF (200 mL) was refluxed for 72 h under an atmosphere of nitrogen. After removing solvent, crude product was recrystallized from hot acetone to afford product **18** (0.38 g, 43.2 %) as a white powder: mp 267 °C (dec.); ¹H NMR (DMSO-*d*₆) δ 11.15, 10.90 (2s, 2H, 2NH), 7.88–7.68 (m, 4H, Ar-H), 4.46 (t, *J* = 7.6 Hz, 1H, C3'-H), 2.71–2.59 (m, 2H) and 2.22–2.08 (m, 2H) ppm; ¹³C NMR (DMSO-*d*₆) δ 173.4, 172.0, 169.2, 152.5, 136.6, 133.9, 132.5, 131.5, 123.1, 122.3, 59.5, 30.4 and 26.1 ppm; MS (CI/CH₄), *m/z* 257 (M⁺). Anal. Calcd for C₁₃H₁₁N₃O₃: C, 60.70; H, 4.31; N, 16.33. Found: C, 60.67; H, 4.38; N, 16.20.

4.1.14. 3-(4-Aza-1, 3-dioxo-1, 3-dihydro-2*H*-isoindol-2-yl)-2, 6-dioxopiperidine (19)—A mixture of 2, 3-pyridinedicarboxylic anhydride (1.0 g, 6.71 mmol) and 3-amino-2, 6-dioxopiperidine trifluoroacetate **15** (1.63 g, 6.73 mmol) in acetic acid (51 mL) was refluxed under an atmosphere of nitrogen for 7.5 h. After removing solvent, crude product was recrystallized from acetone to afford product **19** (0.18 g, 10.3 %) as white needle crystals: mp 266.0–267.5 °C; ¹H NMR (CDCl₃) δ 8.95 (s, br, 1H, C5-H), 8.13 (d, *J* = 9.3 Hz, 1H, C7-H), 8.00 (s, 1H, NH), 7.61 (s, br, 1H, C6-H), 5.11–4.91 (m, 1H, C3'-H), 2.99–2.65 (m, 3H) and 2.21–2.09 (m, 1H) ppm; ¹³C NMR (CDCl₃) δ 170.2, 167.2, 165.2, 165.0, 155.7, 151.3, 131.6, 127.7, 127.2, 49.6, 31.3 and 22.5 ppm; MS (CI/CH₄), *m/z* 259 (M⁺). Anal. Calcd for C₁₂H₉N₃O₄: C, 55.60; H, 3.50; N, 16.21. Found: C, 55.03; H, 3.62; N, 15.74.

4.1.15. 3-(5-Aza-1, 3-dioxo-1, 3-dihydro-2*H*-isoindol-2-yl)-2, 6-dioxopiperidine (20)—A mixture of 3, 4-pyridinedicarboxylic anhydride (1.0 g, 6.71 mmol) and 3-amino-2, 6-dioxopiperidine trifluoroacetate **15** (1.63 g, 6.73 mmol) in acetic acid (51 mL) was refluxed under an atmosphere of nitrogen for 6.5 h. After removing solvent, crude product was recrystallized from acetone to afford product **20** (1.62 g, 93.1 %) as white crystals: mp 234.0–235.5 °C; ¹H NMR (DMSO-*d*₆) δ 11.18 (s, 1H, NH), 9.29–9.10 (m, 2H, C4-H, C6-H), 7.99 (d, *J* = 7.8 Hz, 1H, C7-H), 5.31–5.15 (m, 1H, C3'-H), 3.05–2.39 (m, 3H) and 2.19–2.02 (m, 1H) ppm; ¹³C NMR (DMSO-*d*₆) δ 173.0, 169.9, 166.8, 166.4, 156.7, 144.7, 139.1, 125.7, 117.5, 49.6, 31.2 and 22.1 ppm; MS (CI/CH₄), *m/z* 259 (M⁺). Anal. Calcd for C₁₂H₉N₃O₄: C, 55.60; H, 3.50; N, 16.21. Found: C, 55.65; H, 3.56; N, 15.99.

4.2. Biological assay

RAW 264.7 cells were cultured and treated with thalidomide analogues and LPS as has been previously described.^{6c} In a manner similar to its use herein in cell culture, LPS has been found to elevate TNF-α levels in animals – both systemically as well as within the brain, and to be associated with neurodegenerative disease onset.^{16a,b} The CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) is a commercially used assay that is widely used to quantitatively determine cell proliferation, and this assay was utilized in our studies in line with the manufacturer's guidelines. Changes in cellular health status can be determined by use of indirect measures related to the formation of a colored tetrazolium dye product that can be measured spectrophotometrically at 490 nm. An increase in absorbance at 490 nm is indicative of an increase in cell numbers and thus cell proliferation; and a decrease in absorbance is indicative of cell death. Data are expressed as a percentage change in Optical Densities (O.D.) compared to the appropriate control values. TNF-α

protein levels were measured in culture media by use of an ELISA specific for mouse TNF- α protein (BioLegend MAXTM Mouse TNF- α ELISA Kit, BioLegend, San Diego, CA) and are expressed as a percentage change from the appropriate control.

Acknowledgments

This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (NIH) and by NIH grants (AG18379 and AG18884) to D.K.L. The authors declare that they have no conflicts of interest regarding the contents of this manuscript, and are grateful to Dr. Amy Newman and colleagues of the Medicinal Chemistry Section, National Institute on Drug Abuse, NIH, for use of NMR equipment.

References and notes

1. Irma MS. Alzheimer's & Dementia. 2009; 5:234.
2. (a) Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Mol Neurodegen. 2009; 16:47.(b) Frankola KA, Greig NH, Luo W, Tweedie D. CNS Neurol Disord Drug Targets. 2011; 10:391. [PubMed: 21288189] (c) Reale M, Greig NH, Kamal MA. Mini Rev Med Chem. 2009; 9:1229. [PubMed: 19817713]
3. (a) Walker SL, Waters MF, Lockwood DN. Lepr Rev. 2007; 78:197. [PubMed: 18035771] (b) Van Veen NH, Lockwood DN, van Brakel WH, Ramirez J Jr, Richardus JH. Cochrane Database Syst Rev. 2009; 3:CD006949.(c) Ladizinski B, Shannon EJ, Sanchez MR, Levis WR. J Drugs Dermatol. 2010; 9:814. [PubMed: 20677538] (d) Sissung TM, Thordardottir S, Gardner ER, Figg WD. Anticancer Agents Med Chem. 2009; 9:1058. [PubMed: 19719457]
4. (a) Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. J Exp Med. 1993; 177:1675. [PubMed: 8496685] (b) Sampaio EP, Sarno EN, Gallily R, Cohn ZA, Kaplan G. J Exp Med. 1991; 173:699. [PubMed: 1997652]
5. Pillemer SR, Leakan RA, Sankar V, Manny J, Baum BJ. Arthritis Care & Research. 2004; 51:505. [PubMed: 15188341]
6. (a) Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, Brossi A, Greig NH. J Med Chem. 2003; 46:5222. [PubMed: 14613324] (b) Luo W, Yu QS, Tweedie D, Deschamps j, Parrish D, Holloway HW, Li Y, Brossi A, Greig NH. SYNTHESIS. 2008; 21:3415.(c) Tweedie D, Luo W, Short RG, Brossi A, Holloway HW, Li Y, Yu QS, Greig NH. J Neuroscience Methods. 2009; 183:182.(d) Baratz R, Tweedie D, Rubovitch V, Luo W, Hoffer BJ, Greig NH, Pick CG. J Neurochem. 2011 In review. (e) Kaplan, G.; Sampaio, EP. US Patent. 5,385,901. 1995. Chem Abstr. 1992; 117:226313a.(f) Luzzio FA, Mayorov AV, Ng SSW, Kruger EA, Figg WD. J Med Chem. 2003; 46:3793. [PubMed: 12930142]
7. Zahran MA-H, Salem TA-R, Samaka RM, Agwa HS, Awad AR. Bioorg & Med Chem. 2008; 16:9708. [PubMed: 18951804]
8. (a) Caladas ED, Hosana CM, Miranda MCC, Souza L, Lima JF. J Agric Food Chem. 2001; 49:4521. [PubMed: 11599982] (b) Erian AW, Sherif SM. Tetrahedron. 1999; 55:7957.(c) Wood TF, Gardner JH. J Am Chem Soc. 1941; 63:2741.(d) Bowden K, Chana RS. J Chem Soc, Perkin Trans 2. 1990:2163.(e) Beji M, Sbihi H, Baklouti A, Cambon AJ. Fluorine Chem. 1999; 99:17.(f) Goal A, Mazur SJ, Fattah RJ, Hartmam TL, Turpin JA, Huang M, Rice WG, Appella E, Inman JK. Bioorg Med Chem Lett. 2002; 12:767. [PubMed: 11858998]
9. Zhang, H. China PCT Int Appl. CODEN: PIXXD2 WO 2006105697 A1 20061012 CAN 145: 397376 AN 2006: 1065842.. 2006.
10. Anastas, PT.; Warner, JC. Green Chemistry: Theory and Practice. Oxford University Press; New York: 1998. p. 30
11. (a) Chaulet C, Croix C, Alagille D, Normand S, Delwail A, Favot L, Lecron JC, Viaud-Massuard MC. Bioorg Med Chem Lett. 2011; 21:1019. [PubMed: 21215621] (b) Gordon JN, Prothero JD, Thornton CA, Pickard KM, Di Sabatino A, Goggin PM, Pender SL, Macdonald TT. J Crohns Colitis. 2009; 3:175. [PubMed: 21172267]
12. (a) Muller, GW.; Sirling, DI.; Chen, R. US Patent. 5,635,517. 1997. (b) Muller GW, Chen RS, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling D. Bioorg & Med

- Chem Lett. 1999; 9:1625. [PubMed: 10386948] (c) Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. J Immunol. 1999; 163:380. [PubMed: 10384139] (d) Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF. J Neuroscience. 2006; 26:2467. [PubMed: 16510725] (e) Muller, GW.; Chen, R.; Saindane, MT.; Ge, C. US Patent Application. 20060052609. 2006. (f) Armoiry X, Aulagner G, Facon T. J Clin Pharmacy Therapeutics. 2008; 33:219.
13. (a) Khera TK, Dick AD, Nicholson LB. Prog Retin Eye Res. 2010; 29:610. [PubMed: 20813201] (b) Patil CS, Liu M, Zhao W, Coatney DD, Li F, VanTubergen EA, D'Silva NJ, Kirkwood KL. Mol Ther. 2008; 16:1657. [PubMed: 18682699] (c) Abdelmohsen K, Kuwano Y, Kim HH, Gorospe M. Biol Chem. 2008; 389:243. [PubMed: 18177264] (d) Stamou P, Kontoyiannis DL. Curr Dir Autoimmun. 2010; 11:61. [PubMed: 20173387]
14. (a) Han JH, Beutler B, Huez G. Biochim Biophys Acta. 1991; 1090:22. [PubMed: 1883841] (b) Seko Y, Cole S, Kasprzak W, Shapiro BA, Ragheb JA. Autoimmun Rev. 2006; 5:299. [PubMed: 16782553] (c) Chae M-J, Sung HY, Kim E-H, Lee M, KwaK H, Chae CH, Kim S, Park W-Y. Exp Mol Med. 2009; 41:824. [PubMed: 19949288] (d) Cheneval D, Kastelic C, Fuerst P, Parker CN. J Biomol Screen. 2010; 15:609. [PubMed: 20460250]
15. (a) Park E, Levis WR, Greig NH, Jung E, Schuller-Levis G. J Drugs Dermatol. 2010; 9:330. [PubMed: 20514789] (b) Naureckiene S, Edris W, Ajit SK, Katz AH, Sreekumar K, Rogers KE, Kennedy JD, Jones PG. J Pharmacol Toxicol Methods. 2007; 55:303. [PubMed: 16990017]
16. (a) Banks WA, Robinson SM. Brain Behav Immun. 2010; 24:102. [PubMed: 19735725] (b) Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, Butterfield DA, Banks WA. Brain Behav Immun. 2009; 23:507. [PubMed: 19486646]






Figure 1.
Known thalidomide, EM-12, revlimid and sulfur containing analogues possessing TNF- α action




Figure 2.
Possible Mechanism Forming Intermediate 8






Figure 3.
Possible Mechanism Forming Compound **17**

**Scheme 1.**

Reagents and conditions: (i) Formaldehyde (37% solution in water), N_2 , reflux, 0.5 h; (ii) thionyl chloride, DMF, $0^\circ C$, 1 h; (iii) trifluoroacetic acid, CH_2Cl_2 , N_2 , rt, 22.5 h; (iv) phthalaldialdehyde, THF, N_2 , rt, 71 h; (v) carbon disulfide, cyclohexylamine (for **9**), piperidine (for **10**), CH_3CN , N_2 , rt, 42 to 46 h; (vi) glutarimide (for **11**), dithioglutarimide (for **12**), KOH, CH_3CN , N_2 , rt, 16 to 18 h; (vii) phthalimide (for **13**), dithiophthalimide (for **14**), KOH, CH_3CN , N_2 , rt, 18 h.

**Scheme 2.**

Reagents and conditions: (i) 1,2-Benzenedisulfonyl dichloride, Et_3N , THF, N_2 , reflux, 24 h; (ii) 1,3-diiminoisoindoline, Et_3N , THF, N_2 , reflux, 98 h; (iii) 3-iminoisoindolinone, Et_3N , THF, N_2 , reflux, 72 h; (iv) 2,3-pyridinedicarboxylic anhydride, AcOH, N_2 , reflux, 7.5 h; (v) 3,4-pyridinedicarboxylic anhydride, AcOH, N_2 , reflux, 6.5 h.

Table 1

Inhibition of LPS-induced TNF- α production in RAW 264.7 cells, cell viability and calculated lipophilicity of assayed compounds **9–14**, **16–20** are shown. The anti-TNF- α properties of the analogs are compared with those of revlimid **3**

Compd	TNF- α activity (30 μ M) Control = 100%		Cell viability (30 μ M) Control = 100%		C log D^a	Fold to 1 anti-TNF- α activity b
	% Control	P value	% Control	P value		
3	109 \pm 10	0.4482	106 \pm 3	0.1252	-1.31	1
9	55 \pm 3	<0.001	103 \pm 2	0.1555	+1.39	45
10	96 \pm 1	0.0734	112 \pm 1	<0.0001	+0.65	4
11	79 \pm 3	0.0087	102 \pm 2	0.2028	-1.66	21
12	63 \pm 2	0.0184	94 \pm 3	0.1488	-0.72	37
13	88 \pm 2	0.0571	98 \pm 2	0.4333	-0.48	12
14	52 \pm 2	0.0009	82 \pm 6	0.0427	+0.27	48
16	55 \pm 4	0.0092	109 \pm 3	0.0762	-1.75	45
17	61 \pm 5	0.0154	116 \pm 2	0.0163	-1.98	39
18	67 \pm 5	0.0043	84 \pm 2	0.0018	-2.13	33
19	104 \pm 3	0.4214	95 \pm 5	0.5793	-1.93	-4
20	96 \pm 2	0.5184	96 \pm 4	0.6212	-2.04	4

Presented values are mean \pm S.E.M. of $n = 3$ measurements. A Students t -test was used to assess for statistically significant changes; $P < 0.05$ was considered significant.

a C log D – calculated log D values were determined at pH 7.0 (CompuDrug, Pallas).

b Fold to thalidomide (**1**) anti-TNF- α activity was defined as $(100 - \text{TNF-}\alpha \text{ activity } \%) \text{ Change of every compound} / (100 - \text{TNF-}\alpha \text{ activity } \% \text{ Change contrasted with } \mathbf{1})$, TNF- α activity % control for thalidomide was equal to 99% of levels achieved in the presence of vehicle. The TNF-activity of compound **17** compares favorably with that of A10 in Ref. 6c.